Matches in SemOpenAlex for { <https://semopenalex.org/work/W3089935301> ?p ?o ?g. }
- W3089935301 endingPage "32" @default.
- W3089935301 startingPage "21" @default.
- W3089935301 abstract "Background Respiratory syncytial virus (RSV) is the most common cause of severe lower respiratory tract infection, with a high global health burden. There are no effective treatments available. ALX-0171 is a novel trivalent Nanobody with antiviral properties against RSV. We aimed to assess the safety and antiviral activity of nebulised ALX-0171 in children admitted to hospital with RSV lower respiratory tract infection. Methods This double-blind, randomised, placebo-controlled, phase 2b trial was done in 50 hospital paediatric departments across 16 countries. Previously healthy children aged between 28 days to younger than 24 months who were admitted to hospital with RSV acute severe lower respiratory tract infection were randomly assigned in three sequential safety cohorts (3:1) to receive nebulised ALX-0171 (cohort 1 received 3 mg/kg, cohort 2 received 6 mg/kg, and cohort 3 received 9 mg/kg) or placebo once daily for 3 days using web-based randomisation in the sequential safety part (first block size 12, subsequently four). In a parallel part of the study, participants (cohort 4) were randomly assigned (parallel 1:1:1:1) to receive nebulised ALX-0171 3 mg/kg, 6 mg/kg, 9 mg/kg, or placebo (blocks of eight by restricted randomisation). Study drug masking was by two consecutive nebulisations (each either ALX-0171 or placebo) depending on assigned treatment group. The primary outcome was to evaluate time for the RSV viral load to drop to below quantifiable limit, measured by plaque assay on mid-turbinate nasal swabs. Safety, clinical efficacy, pharmacokinetics, viral load by RT-qPCR, and immunogenicity were secondary outcomes. Analysis, including of the primary outcome, was by modified intention to treat (participants receiving at least one dose of study drug as assigned), and safety was assessed in all children who received at least one administration of study drug, as treated. This trial is registered with EudraCT, 2016-001651-49. Findings Between Jan 10, 2017, and April 26, 2018, 175 children (median age 4·8 months [IQR 2·0–10·8]), received at least one dose of study drug (45 received 3 mg/kg of ALX-0171, 43 received 6 mg/kg of ALX-0171, 45 received 9 mg/kg of ALX-0171, and 42 received placebo; the modified intention-to-treat population) commencing at a mean 3·3 days (SD 1·1) from symptom onset. Median time for the viral load to drop to below quantifiable limit on plaque assay was significantly faster for the 3 mg/kg group (median 14·2 h [IQR 5·0–28·0]), 6 mg/kg group (5·1 h [4·7–28·5]), and 9 mg/kg group (5·1 h [4·6–5·9]) than the placebo group (46·1 h [25·2–116·7]; hazard ratio [HR] all ALX-0171 groups vs placebo 2·6 [1·7–3·9]; p<0·0001). Median time for the viral load to drop below quantification limit with RT-qPCR was 95·9 h (IQR 26·7 to not estimable) for the placebo group (n=35) versus 49·4 h (25·1 to 351·4) for all ALX-0171 groups (n=118). Clinical outcomes were not improved by ALX-0171 compared with placebo, with no difference in time to clinical response (oxygen saturation >92% for 4 h in room air and adequate oral feeding) in ALX-0171 groups and the placebo group (median 43·8 h [IQR 21·7–68·5] vs 47·9 h [22·5–76·4]; HR 1·1 [95% CI 0·8–1·6]) or change in the global severity score from baseline to 5 h post-dose on day 2 (−4 [IQR −6 to −2] vs −4 [–6 to −1]; difference in least-squares mean −0·45 [95% CI −1·39 to 0·49]). Serum concentrations of ALX-0171 on day 2 exceeded the concentration estimated to give full RSV neutralisation in the lung at 6 mg/kg and 9 mg/kg doses. Treatment-emergent antidrug antibodies were detected at day 14 in 46 (34%) of 135 patients who received ALX-0171 and ten (26%) of 39 patients who received placebo. Serious adverse events were reported in five (13%) of 40 children in the placebo group and ten (7%) of 135 children in all ALX-0171 groups, leading to study drug discontinuation in three children (two in the 3 mg/kg group and one in the 6 mg/kg group). 13 of 15 serious adverse events (three of four in the 3 mg/kg group, two of three in the 6 mg/kg group, three of three in the 9 mg/kg group, and five of five in the placebo group) were related to worsening respiratory status, and none were considered to be related to the study drug. Interpretation Antivirals against RSV might be unable to improve clinical course once RSV lower respiratory tract infection is established. Future studies of RSV antivirals should focus on earlier intervention and more precise measurement of objective outcomes before the onset of significant lower respiratory tract inflammation. Funding Ablynx, a Sanofi Company." @default.
- W3089935301 created "2020-10-08" @default.
- W3089935301 creator A5003213694 @default.
- W3089935301 creator A5012431735 @default.
- W3089935301 creator A5013618589 @default.
- W3089935301 creator A5018223294 @default.
- W3089935301 creator A5019574548 @default.
- W3089935301 creator A5021073773 @default.
- W3089935301 creator A5021333859 @default.
- W3089935301 creator A5021536267 @default.
- W3089935301 creator A5022507215 @default.
- W3089935301 creator A5023135428 @default.
- W3089935301 creator A5023791457 @default.
- W3089935301 creator A5028362908 @default.
- W3089935301 creator A5028999538 @default.
- W3089935301 creator A5029310736 @default.
- W3089935301 creator A5030526501 @default.
- W3089935301 creator A5035034619 @default.
- W3089935301 creator A5038213265 @default.
- W3089935301 creator A5039504537 @default.
- W3089935301 creator A5044810291 @default.
- W3089935301 creator A5047558403 @default.
- W3089935301 creator A5051415816 @default.
- W3089935301 creator A5051559120 @default.
- W3089935301 creator A5052443294 @default.
- W3089935301 creator A5053591593 @default.
- W3089935301 creator A5053719643 @default.
- W3089935301 creator A5053772167 @default.
- W3089935301 creator A5055643885 @default.
- W3089935301 creator A5055748703 @default.
- W3089935301 creator A5055859466 @default.
- W3089935301 creator A5056942668 @default.
- W3089935301 creator A5057808964 @default.
- W3089935301 creator A5058637049 @default.
- W3089935301 creator A5061988295 @default.
- W3089935301 creator A5062706301 @default.
- W3089935301 creator A5062757576 @default.
- W3089935301 creator A5063458648 @default.
- W3089935301 creator A5064984140 @default.
- W3089935301 creator A5065220619 @default.
- W3089935301 creator A5066009579 @default.
- W3089935301 creator A5068424450 @default.
- W3089935301 creator A5071106356 @default.
- W3089935301 creator A5071391168 @default.
- W3089935301 creator A5072661798 @default.
- W3089935301 creator A5073117656 @default.
- W3089935301 creator A5073512922 @default.
- W3089935301 creator A5076167404 @default.
- W3089935301 creator A5077925330 @default.
- W3089935301 creator A5078205064 @default.
- W3089935301 creator A5081927944 @default.
- W3089935301 creator A5082308297 @default.
- W3089935301 creator A5082359156 @default.
- W3089935301 creator A5083784244 @default.
- W3089935301 creator A5084887081 @default.
- W3089935301 creator A5085811822 @default.
- W3089935301 creator A5087008695 @default.
- W3089935301 creator A5088037538 @default.
- W3089935301 creator A5091863505 @default.
- W3089935301 date "2021-01-01" @default.
- W3089935301 modified "2023-10-16" @default.
- W3089935301 title "Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial" @default.
- W3089935301 cites W1836636493 @default.
- W3089935301 cites W1877919713 @default.
- W3089935301 cites W1957115089 @default.
- W3089935301 cites W1963801464 @default.
- W3089935301 cites W2028941141 @default.
- W3089935301 cites W2044022781 @default.
- W3089935301 cites W2046434535 @default.
- W3089935301 cites W2065401799 @default.
- W3089935301 cites W2102247672 @default.
- W3089935301 cites W2103353840 @default.
- W3089935301 cites W2109831018 @default.
- W3089935301 cites W2119804593 @default.
- W3089935301 cites W2119850418 @default.
- W3089935301 cites W2146453977 @default.
- W3089935301 cites W2156304672 @default.
- W3089935301 cites W2159774234 @default.
- W3089935301 cites W2167981735 @default.
- W3089935301 cites W2334783812 @default.
- W3089935301 cites W2335562578 @default.
- W3089935301 cites W2432608323 @default.
- W3089935301 cites W2469823074 @default.
- W3089935301 cites W2565115490 @default.
- W3089935301 cites W2586676015 @default.
- W3089935301 cites W2727509207 @default.
- W3089935301 cites W2730597558 @default.
- W3089935301 cites W2738322136 @default.
- W3089935301 cites W2752174290 @default.
- W3089935301 cites W2768444833 @default.
- W3089935301 cites W2794963435 @default.
- W3089935301 cites W2799481379 @default.
- W3089935301 cites W2896802097 @default.
- W3089935301 cites W2900617424 @default.
- W3089935301 cites W2944437597 @default.
- W3089935301 cites W2994983097 @default.
- W3089935301 cites W3007375334 @default.
- W3089935301 doi "https://doi.org/10.1016/s2213-2600(20)30320-9" @default.